About ViGenCell
ViGenCell is a publicly listed company based in Seoul (South Korea) founded in 2013, and was acquired by Boryung Pharmaceutical in August 2017. T-cell therapies for tumor treatment are developed by ViGenCell. The company has 63 employees. Its chief executive, as recorded, is Kim Tae-gyu. Its website vigencell.com draws about 16 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
ViGenCell provides therapeutics solution for tumor based on immunological cells. It provides its propriety immunocytochemistry technology to improve the immunity of patients while tumors surgery, drug therapy, and radiotherapy. The leading candidate of the company are ViTier (CTL), ViRager ( γδT ), ViMedier (CBMS) involve in NK T cell lymphoma, acute bone marrow, Blood cancer, glioblastoma, solid cancer, graft-versus-host disease, and others, are in phase 1 and pre-clinical stage.
- Headquarters Seoul, South Korea
- Employees 63
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website vigencell.com
- Acquired by Boryung Pharmaceutical (Aug 2017)
- Legal Name Vigencell, Inc.
- Annual Revenue$15.7 K (USD)-91.87as on Dec 31, 2025
- Net Profit-$11.3 M (USD)-16.13as on Dec 31, 2025
- EBITDA-$9.78 M (USD)-20.79as on Dec 31, 2025
- Investors
- Employee Count63
- Acquired byBoryung Pharmaceutical
(Aug 2017)
Investors in ViGenCell
ViGenCell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boryung Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finished formulations and APIs are developed for diverse disease areas. | 1963 | boryung.co.kr | Seoul, South Korea |
Investor details for ViGenCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ViGenCell
1 people are tracked at ViGenCell (1 in leadership); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Kim Tae-gyu | CEO | Leadership |
Complete people profiles for ViGenCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ViGenCell
ViGenCell is a publicly listed company on the KRX with ticker symbol 308080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Aug 2021
- Listed onKRX: 308080
- Listed entityViGenCell, Inc.
- Exchange sectorHealth technology
- ISINKR7308080001
- Share price5,420.00 KRW (-1.81% on the day) · 2026-10-14
- Market capitalisation113,155,914,917.00 KRW
- EPS (diluted, trailing year)-647.86 KRW
- Volume (last session)38,553
Financials of ViGenCell
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 22.7M KRW | -16.32B KRW | -14.13B KRW |
| 2024 | 278.9M KRW | -14.06B KRW | -11.70B KRW |
| 2023 | -17.88B KRW | -15.99B KRW | |
| 2022 | -17.39B KRW | -15.30B KRW | |
| 2021 | -11.11B KRW | -11.42B KRW |
Detailed financial statements for ViGenCell
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ViGenCell
3 dated milestones of ViGenCell across 8 years, from founding to its latest funding, stage changes and deals.
- Founded ViGenCell is founded.
- Exit Acquired by Boryung Pharmaceutical.
- IPO Lists on the stock exchange (IPO).
Web traffic of ViGenCell
The website of ViGenCell (vigencell.com) receives about 15.7K visits a month.
- Monthly visits15.7K
▼ 46.2% vs previous month
Websites whose visitors overlap most with ViGenCell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biospectator.com | 100% | #147,558 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vigencell
Complete news archive for ViGenCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViGenCell
ViGenCell was founded in 2013.
ViGenCell is headquartered in Seoul, South Korea.
Kim Tae-gyu is the CEO of ViGenCell, as recorded in our data.
ViGenCell has 63 employees.
Annual revenue of ViGenCell is $15.7K as on Dec 31, 2025.
ViGenCell provides therapeutics solution for tumor based on immunological cells. It provides its propriety immunocytochemistry technology to improve the immunity of patients while tumors surgery, drug therapy, and radiotherapy. The leading candidate of the company are ViTier (CTL), ViRager ( Ξ³Ξ΄T ), ViMedier (CBMS) involve in NK T cell lymphoma, acute bone marrow, Blood cancer, glioblastoma, solid cancer, graft-versus-host disease, and others, are in phase 1 and pre-clinical stage.
Yes, ViGenCell is publicly traded on KRX under the ticker symbol 308080.
ViGenCell has 1 investor. Key investors include Boryung Pharmaceutical.
Yes. ViGenCell was acquired by Boryung Pharmaceutical in August 2017.